“…Although pulse steroid therapy involves single administrations of the same amount of steroids administered over 1 month in standard treatment, it has been suggested that the reason why it has fewer side effects relative to the amount used is that the serum pharmacokinetics of methylprednisolone in pulse steroid therapy are different from those of prednisolone, which is administrated orally and intravenously in standard treatment. In other words, as reported by Vree et al [17], although the half-life of the prednisolone that is administrated orally and intravenously in standard treatment is 2.7–3.7 h [13,14,15,16], the half-life of methylprednisolone used in pulse steroid therapy is shortened to 1.4 h [17]. In sum, there is a possibility that the fact that the half-life of methylprednisolone in pulse steroid therapy is half of that of the prednisolone of standard treatment contributes to the reduction of side effects.…”